RecruitingNot ApplicableNCT04586166

Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy

SASS: Randomized Trial of Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for Concomitant Management of Stress Urinary Incontinence During Minimally Invasive Sacrocolpopexy


Sponsor

Wake Forest University Health Sciences

Enrollment

180 participants

Start Date

Dec 23, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

SASS (Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy) will be a multicenter, prospective, randomized, single-blind non-inferiority trial.


Eligibility

Sex: FEMALEMin Age: 21 Years

Inclusion Criteria7

  • At least 21 years of age
  • Vaginal bulge symptoms as indicated by an affirmative response of \>1 to question 3 of the PFDI-SF20
  • POP ≥ stage II according to the pelvic organ prolapse quantification (POP-Q) system45, with evidence of apical descent
  • Women being considered for minimally invasive sacrocolpopexy (with or without concomitant hysterectomy)
  • Objective SUI: positive standardized cough stress test on clinical examination or on urodynamic study with reduced prolapse
  • Understanding and acceptance of the need to return for all scheduled follow-up visits and willing to complete study questionnaires
  • Able to give informed consent

Exclusion Criteria13

  • Prior surgery for stress urinary incontinence including mid-urethral sling; Burch/MMK; fascial pubovaginal sling (autologous, xenograft or allograft); and urethral bulking injection
  • Any serious disease, or chronic condition, that could interfere with the study compliance
  • Unwilling to have a synthetic sling
  • Untreated and unresolved urinary tract infection
  • Poorly-controlled diabetes mellitus (HgbA1c \> 9 within 3 months of surgery date)
  • Neurogenic bladder/ pre-operative self-catheterization
  • Elevated post-void residual/PVR (\>150 ml) that does not resolve with prolapse reduction testing (pessary, prolapse reduced uroflow or micturition study)
  • Prior pelvic radiation
  • Inflammatory bowel disease
  • Current genitourinary fistula or urethral diverticulum
  • Planned concomitant bowel related surgery including sphincteroplasty and perineal rectal prolapse surgery, rectovaginal fistula repair, hemorrhoidectomy
  • Pregnant or Planning to Conceive
  • Incarcerated

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICERP Sling

Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.

DEVICESIS

Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.


Locations(7)

Augusta University

Augusta, Georgia, United States

Northwestern Medicine

Chicago, Illinois, United States

University of Chicago

Chicago, Illinois, United States

Boston Urogynecology Associates

Cambridge, Massachusetts, United States

Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, United States

Pelvic Floor Foundation of South Africa, University of Cape Town

Cape Town, South Africa

Florida Robotic and Minimally Invasive Urogynecology

Coconut Creek, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04586166


Related Trials